Executing on Our Strategy
King Pharmaceuticals is achieving its vision through an enterprise-wide focus on its target, specialty driven markets, organic growth and a disciplined business development process.
The specialty driven markets in which King is focused, particularly neuroscience, hospital and acute care, represent markets in which King has core capabilities and assets. Additionally, King has an existing strong presence and demonstrated commitment to meeting the needs of patients and physicians in these target markets.
The company’s strategic plan is designed to achieve long-term value for its shareholders through organic growth and business development.
Organic growth
- Maximizing the potential of currently marketed products: King has a strong portfolio of core marketed products. These products provide revenue and cash flow that enable King to invest in the future of the company through the continuing development of products in the company's pipeline and business development collaborations that add innovative products and technologies to King's portfolio of products in development.
- Developing pipeline products through King’s R&D team: King’s 100-person strong in-house R&D team includes drug development scientists, regulatory and drug safety staff who manage the full range of R&D activities for late-stage products, including: drug discovery, clinical development, drug safety, regulatory affairs, medical affairs and project management. Additionally, King has established a highly cost-effective and efficient R&D model that sets it apart from other pharmaceutical companies.
Business Development
- Acquisition of companies and late stage compounds and developing partnerships for promising products and technologies. King has a highly-disciplined, best-in-class business development process. Through rigorous and focused screening, King is able to identify opportunities most aligned with the company’s strengths and strategy – to mutually benefit King, its business partners and the healthcare needs of the populations served. In December 2008, King completed its acquisition of Alpharma Inc., creating a leading specialty pharmaceutical company with greater scale and capabilities and an expanded portfolio of pain management products and strengthened pipeline. Additionally, with a focus on late stage development opportunities, King has entered into several collaborations, including its strategic alliances with Pain Therapeutics and Acura Pharmaceuticals to develop and commercialize opioid products that resist or deter common methods of abuse. These opportunities directly align with King’s emphasis on its neuroscience, hospital and acute medicine platforms, particularly King’s pain management franchise.
- As a result of our business development initiatives, King is now better positioned to develop a full complement of existing opioid compounds to better address patient’s, physician’s and managed care’s needs by utilizing formulation technologies designed to offer effective pain relief while deterring common methods of abuse.
- Expanding our markets - King also seeks to expand its markets into Canada and the European Union.
